- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04152356
Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma
November 3, 2019 updated by: TaoBai, Guangxi Medical University
Study on Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma
Liver cancer is a common malignant tumor in China, and its incidence rate ranks third and remains high.
The treatment of liver cancer has made some progress in recent years, mainly the progress of radical treatment such as surgery and ablation.
For liver cancer, due to the emergence of molecularly targeted drugs such as sorafenib and immunological checkpoint inhibitors, the systemic therapeutic effect of advanced liver cancer is improved, and the curative effect is further improved.
In recent years, immunotherapy has become one of the clinical treatment options for cancer.
T lymphocytes are a cell with cell killing ability in the immune system, and programmed death factor 1 (PD-1) is an important inhibitory receptor on the surface of T lymphocytes.
It is known that the ligands of PD-1 are PD-L1 and PD-L2, and studies have found that a variety of tumor cells have high expression of PD-L1 ligand on the surface.
At present, clinical research on target drugs for PD-1 has included dozens of solid tumors or hematological tumors.
The results of clinical studies that have been completed and the interim results of some studies indicate that anti-PD-1 antibody drugs are more effective and safer than previous treatments.
Patients with hepatocellular carcinoma (HCC) often undergo liver cancer resection, but the recurrence rate can reach 70% to 100%, which seriously affects the treatment outcome and long-term survival rate.
Early recurrence of liver cancer is mainly related to the invasiveness of the tumor.
Microvascular invasion, non-anatomical hepatectomy, AFP greater than 32 ng/ml, tumor diameter greater than 5 cm, and incomplete tumor capsule are risk factors for recurrence within 2 years after surgery.
Hence, it is necessary to determine the risk factors for HCC recurrence and the markers for continuous monitoring of anti-tumor response before and after surgery.
Circulating tumor cells (CTCs) is an integral part of "liquid biopsy" and has great potential to change the current treatment modality in the cancer field.
CTCs are derived from solid tumors and are associated with hematogenous metastasis.
Therefore, analyzing the level of CTC has clinical guiding significance.
For liver cancer patients, overall survival (OS) tended to be poorer in patients with CTCs.
Although surgical treatment of liver cancer has benefited most patients with liver cancer, monitoring postoperative recurrence, further improving the long-term prognosis of liver cancer, postoperative detection of CTCs and other related indicators, combined with targeted, immune and other related treatments for further study.
It is expected to receive 100 patients (50 treatment groups, 50 control groups).
Patients who underwent immunotherapy after surgery were assigned to the immunotherapy group, and patients who were not treated with sorafenib after surgery were classified as the control group.
All patients underwent 7 CTCs tests (immunomagnetic beads negative enrichment-targeted PCR) before, 7 days after surgery and 1st, 3rd, 6th, 9th, and 12th postoperatively.
All patients were observed from the observation period.
After the liver cancer resection, the patient was observed to have died, lost to follow-up or the end of the study.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangxi
-
Nanning, Guangxi, China, 530000
- Recruiting
- TaoBai
-
Contact:
- Tao Bai, MD
- Phone Number: +86 13878862632
- Email: 25859373@qq.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
That was diagnosed with hepatocellular carcinoma at the Affiliated Tumor Hospital of Guangxi Medical University after November 1, 2019.
Patients underwent liver cancer resection and complete resection of the naked eye and postoperative imaging without residual cancer; no large blood vessels (level 2 branches) and Invasion of the bile duct, no gross tumor thrombus; negative margin: the margin of the liver is >1 cm from the tumor boundary; if the margin is <1 cm, but the histological examination of the liver section is free of residual tumor cells, that is, the margin is negative; AFP is negative: 20 ug/L; no lymph node involvement, no distant metastasis.
Description
Inclusion Criteria:
- Pathological diagnosis of primary hepatocellular carcinoma, BCLC stage A, liver function Chid-Pugh grade A, or liver function Child-Pugh classification changed from grade B to grade A after short-term liver treatment, PS score 0- 1 point. Received surgical treatment of primary hepatocellular carcinoma (RO resection).
- Complete resection of postoperative macroscopic and imaging, no residual cancer;
- No large blood vessels (2-pole branches) and bile duct invasion, no macroscopic tumor thrombus;
- Negative margin: the margin of the liver is >1 cm from the tumor boundary; if the margin is <1 cm, but the histological examination of the resected liver section showed no residual tumor cells, that is, the margin was negative;
- AFP negative: <20 ug/L;
- No lymph node invasion, no distant metastasis;
Laboratory inspection inclusion criteria:
- Neutrophils ≥ 1.5 × 109 / L;
- Platelets ≥ 50 × 109 / L;
- Hemoglobin ≥ 90 g / L;
- Serum creatinine ≤ 1.5 × upper limit of normal (ULN) and creatinine clearance ≥ 50 mL/min;
- AST, ALT ≤ 2.5 × ULN;
- Serum bilirubin ≤ 1.25 × ULN;
- Patients who did not receive anticoagulant therapy: INR or aPTT ≤ 1.5 × ULN. If the patient received prophylactic anticoagulant therapy, the INR ≤ 2 × ULN within 14 days before the study treatment and the aPTT was within the normal range, the patients were acceptable for enrollment.
With one of the following high risk factors:
- Single lesion >5cm;
- Single lesion, 3-5cm, with MVI M1/M2;
- Single lesion, <3cm, MVI M2;
- Multiple lesions (2-3)
General inclusion criteria:
- Age 18-75;
- No anti-tumor treatment history before surgery;
- Agree to provide tissue and pathological specimens;
- ECOG 0 points;
- For women of gestational age, no pregnancy plan and continued full contraception.
Exclusion Criteria:
- Pathological diagnosis of primary hepatocellular carcinoma, BCLC stage B, C, D, liver function Child-Pugh grade C, PS score of 2 points and above. Biliary cells or mixed cell carcinoma confirmed by postoperative pathology. No surgery was performed.
- Preoperative treatment of TACE or radiotherapy and chemotherapy, and targeted anti-tumor therapy.
- One month after the operation, the rest of the anti-tumor treatment was performed, or combined with two or more anti-tumor pain treatment.
- There were lymph nodes and distant metastases before surgery.
- Have a history of active autoimmune disease or autoimmune disease;
- Inoculated with any anti-infective vaccine (such as influenza vaccine, varicella vaccine, etc.) within 4 weeks before randomization;
- Use immunosuppressive agents, or systemic, or absorbable local hormones to achieve immunosuppressive purposes (dose > 10 mg/day of prednisone or other equivalent hormones) and continue to be used within 2 weeks prior to randomization;
- Any significant clinical and laboratory abnormalities;
- Researchers believed that the patient effected safety evaluation, such as: uncontrollable active infections, uncontrolled diabetes, high blood pressure could not be reduced to the following range by monotherapy (systolic blood pressure < 140 mmHg, diastolic blood pressure < 90 mmHg), peripheral neuropathy grade II or above, congestive heart failure, myocardial infarction within 6 months, chronic kidney disease;
- Main or main branch tumor thrombus (preoperative imaging or intraoperative findings) or extrahepatic disseminated or recurrent liver cancer.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
PD-1
|
PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues.
It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11.
Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti-autoimmune diseases and organ transplant survival.
Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role.
PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
|
Sorafenib
|
Sorafenib tosylate is a novel multi-target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels.
It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet-derived growth factor (PDGF) receptors.
Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease-free Survival
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 1, 2019
Primary Completion (Anticipated)
August 1, 2020
Study Completion (Anticipated)
September 1, 2020
Study Registration Dates
First Submitted
October 20, 2019
First Submitted That Met QC Criteria
November 3, 2019
First Posted (Actual)
November 5, 2019
Study Record Updates
Last Update Posted (Actual)
November 5, 2019
Last Update Submitted That Met QC Criteria
November 3, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Sorafenib
Other Study ID Numbers
- GuangXiMU-HCC-PD1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HepatoCellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
Clinical Trials on PD-1
-
Shanghai Zhongshan HospitalRecruiting
-
RWJ Barnabas Health at Jersey City Medical CenterUnknown
-
Peking UniversityNot yet recruitingGastroesophageal Junction Cancer | Chemoradiotherapy | PD-1
-
The First Affiliated Hospital of Guangdong Pharmaceutical...University of Technology, Sydney; Guangzhou Anjie Biomedical Technology Co....UnknownNon-small Cell Lung Cancer | Lung Neoplasm MalignantChina
-
Sinocelltech Ltd.UnknownHead and Neck Squamous Cell CarcinomaChina
-
University of Colorado, DenverNational Cancer Institute (NCI); Cancer League of ColoradoWithdrawnColorectal Cancer | Microsatellite Instability High | Mismatch Repair DeficiencyUnited States
-
Tongji HospitalNational Natural Science Foundation of ChinaRecruitingEsophageal Squamous Cell Carcinoma | Neoadjuvant TherapiesChina
-
Centre Leon BerardNETRIS PharmaRecruitingAdvanced Solid Tumors | Metastatic Solid TumorsFrance
-
Thomas MarronRecruiting
-
Tongji UniversityRecruitingA Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver MutationsNSCLC, Stage IIIA | EGF-R Negative Non-Small Cell Lung Cancer | ALK Negative NSCLCChina